K
76.58
0.31 (0.41%)
| Previous Close | 76.27 |
| Volume | 447,109 |
| Price / Earnings (Forward) | 59.52 |
| Price / Sales | 7.42 |
| Price / Book | 9.09 |
| 52 Weeks Range |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Kiniksa Pharmaceuticals Interna | Mixed | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | NA |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Spruce Street Capital Lp | 30 Jun 2026 | 918,070 |
| Driehaus Capital Management Llc | 30 Jun 2026 | 718,199 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEGNA MICHAEL R | - | 79.88 | -10,131 | -808,660 |
| MOAT ROSS | - | 79.28 | -4,007 | -317,675 |
| PAOLINI JOHN F. | - | 79.28 | -4,029 | -319,419 |
| PATEL SANJ K | - | 79.28 | -15,144 | -1,200,616 |
| RAGOSA MARK | - | 79.28 | -4,404 | -349,149 |
| Aggregate Net Quantity | -37,715 | |||
| Aggregate Net Value ($) | -2,995,519 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 79.48 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MEGNA MICHAEL R | Officer | 03 Sep 2026 | Automatic sell (-) | 4,600 | 80.47 | 370,162 |
| MEGNA MICHAEL R | Officer | 01 Sep 2026 | Disposed (-) | 5,531 | 79.28 | 438,498 |
| MEGNA MICHAEL R | Officer | 01 Sep 2026 | Option execute | 11,496 | - | - |
| MOAT ROSS | Officer | 01 Sep 2026 | Disposed (-) | 4,007 | 79.28 | 317,675 |
| MOAT ROSS | Officer | 01 Sep 2026 | Option execute | 8,285 | - | - |
| PAOLINI JOHN F. | Officer | 01 Sep 2026 | Disposed (-) | 4,029 | 79.28 | 319,419 |
| PAOLINI JOHN F. | Officer | 01 Sep 2026 | Option execute | 8,328 | - | - |
| PATEL SANJ K | Officer | 01 Sep 2026 | Disposed (-) | 15,144 | 79.28 | 1,200,616 |
| PATEL SANJ K | Officer | 01 Sep 2026 | Option execute | 31,318 | - | - |
| RAGOSA MARK | Officer | 01 Sep 2026 | Disposed (-) | 4,404 | 79.28 | 349,149 |
| RAGOSA MARK | Officer | 01 Sep 2026 | Option execute | 9,104 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |